NPRA Banner

               
Product Search   QUEST3+ System   Enquiries   Sitemap  

Product Recall

Definition

Product recall is a process taken by the manufacturer, importer and wholesaler to remove or withdraw a particular products from all links of distribution.

The removal or withdrawal may be due to critical quality defects discovered or serious adverse drug reactions reported which might cause health risks to users of the products.


Decision For Recall

The decision for recall shall be made when there is or may caused potential risk to the user of the products by reason of faulty production or on medical grounds:

a) Voluntarily undertaken by the manufacturers and distributors.

b) As directed by the Director of Pharmaceutical Services, Ministry of Health.

Unless the Director of Pharmaceutical Services, Ministry of Health has already specified the degree and level of a particular products recall, the degree and level will be decided by the company’s Product Recall Committee based on risks involved. The Product Recall Committee shall comprise of personnel who are responsible for the execution and coordination of recall. The persons responsible shall handle all aspects of the recalls with the appropriate degree of urgency.

No recall shall take place without first consulting/informing the Authority.

Recalls that involve specific batch will not involve any other batch/batches that currently available in the market.

Not all recalls are initiated because a product is deemed unsafe or ineffective. A recall may also be conducted to remove products from the Malaysian market with quality defects that do not affect their safety and efficacy.

 

Degree of Recall

 

The degree of recall is classified according to the severity of quality defects and adverse reactions of the products.


Degree Definition Recall Notice by PRH
I Products with major health risks that might cause serious injuries or death. Should be under an embargo within 24 hours Within 24 hours of recall commencement or directive
II Products with minor health risks or are substandard. Should be under an embargo within 72 hours Within 48 hours of recall commencement or directive
III Products with other reasons for recall that can cause health risks to users. Should be under an embargo within 30 days or as specified Within 72 hours of recall commencement or directive
 

Level of Recall

The level of recall depends on the nature of problem, extent of the product’s distribution and degree of hazard involved.

Level A: To all consumers (end users).

Level B: To all points of sales (e.g. Hospitals, Pharmacies, Clinics, Specialist Centres).

Level C: To all sub-distributors (wholesalers).


Public Notification

Not all recalls are announced in press releases. However, when a product that has been widely distributed or poses a serious health hazard is recalled, NPRA may do so if the agency determines it is necessary to protect consumers.

 
References: 

1) Drug Registration Guidance Document (DRGD)

2) Guideline on Good Distribution Practice

 

Products as listed below have been recalled from the market.

Year 2026

 

No

Product Name

Registration Number

Active ingredients

Batch Number

Reason for Recall

Degree and Level of Recall

Registration Holder

Date of recall

1

COREDIN PAEDIATRIC LINCTUS

MAL19880311AZ

  1. Ammonium Chloride
  2. Diphenhydramine Hydrochloride

19574, 19616

Precautionary measure following a complaint regarding the presence of particles confirmed to have originated from sugar crystallization in the product formulation.

Voluntary recall at the point of sub-distributor (wholesaler)

TERAPUTICS SDN BHD

30 January 2026

2

VAMLO TABLETS 10MG

MAL07010993AZ

Amlodipine 

24030132

Out of Trend (OOT) result for Related Substances “Impurity D” test at 18th month timepoint of stability study.

Voluntary recall up to the point of sales

RANBAXY (MALAYSIA) SDN. BHD.

13 February 2026

3

DOXYCILLIN TABLET 100MG

MAL19860580AZ

Doxycycline Hydrochloride/ Hyclate

2403300, 2403301, 2405293

Out of specification result for related substance “Impurity C” test during the stability study.

Voluntary recall up to the point of sales

DUOPHARMA MANUFACTURING (BANGI) SDN. BHD.

19 February 2026

4

Uphamol Menstrual Tablet 500/25mg

MAL12025061X

  1. Paracetamol
  2. Pamabrom

2310222

Out-of-specification result was observed for the dissolution test during the stability study.

Voluntary recall up to the point of sales

Duopharma Marketing Sdn. Bhd.

9 February 2026

5

Pro-Stisol Waist & Body Tonic Tablet

MAL16100054T

  1. Cornus officinalis
  2. Dioscorea opposita
  3. Radix Rehmanniae Glutinosa

013/2412 T22-004

The batch tested by NPRA had failed physical appearance test

Degree III recall up to the point of sales

Pro Stisol Manufacturing 

13 Mac 2026

6

Vitamode Astaxanthin Plus Glutathione Capsule

MAL15045003NC

  1. L-glutathione
  2. Haematococcus Pluvialis Extract

5NC10503

Product labelling on the blister strip found to be incorrect.

Voluntary recall up to the point of sales

Medispec (M) Sdn. Bhd.

16 Mac 2026

Last updated 23/04/2026

Year 2025
Year 2024
Year 2023

 

National Pharmaceutical Regulatory Agency (NPRA)

Lot 36, Jalan Universiti (Jalan Prof Diraja Ungku Aziz), 46200 Petaling Jaya, Selangor, Malaysia.

  • Phone: +603-7883 5400

 

 

DISCLAIMER

The Government of Malaysia and the National Pharmaceutical Regulatory Agency are not responsible for any loss or damage caused by the usage of any information obtained from this website.

Site Last Modified

  • Last Modified: Thursday 30 April 2026, 14:52:24.
© Copyright 2024 . All Rights Reserved National Pharmaceutical Regulatory Agency NPRA Site Map

Search

Main Menu English